GAITHERSBURG, Md., May 4, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in the BofA Securities 2023 Health Care Conference.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Thursday, May 11, 2023 | |||||
Time: | 10:00 – 10:30 a.m. Pacific Daylight Time (PDT) | |||||
Location: | Encore Hotel in Las Vegas, Nevada | |||||
Moderator: | Alec Stranahan, Ph.D., Equity Research Analyst – Biotechnology | |||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer and Filip Dubovsky, M.D., President, Research & Development | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, May 10, 2023 - Thursday, May 11, 2023 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined.
Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz | 240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan or Giovanna Chandler | 240-709-5563
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.63 |
| Daily Change: | -0.37 -4.11 |
| Daily Volume: | 3,758,255 |
| Market Cap: | US$1.380B |
December 13, 2024 December 10, 2024 November 11, 2024 October 16, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
